Business
CHOSA: DRP® platform expansion and clinical progress drive CHOSA Oncology's Q1 2025 focus
CHOSA: DRP® platform expansion and clinical progress drive CHOSA Oncology's Q1 2025 focus
About this update from Chosa Oncology Ab
CHOSA Oncology expanded its DRP® platform to predict responses to both cisplatin and carboplatin, advancing studies in lung and breast cancer. Q1 2025 saw a net loss of -1,807 TSEK and strong equity ratio, with key clinical milestones expected in Q2.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.